2004
DOI: 10.7202/008535ar
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacologie du cannabis et synthèse des analyses des principaux comités d’experts

Abstract: RésuméLa première partie de cette étude est une exposition simplifiée de la pharmacologie du cannabis, la substance illicite la plus consommée au Québec, au Canada et dans le monde. Le cannabis contient plus de 460 produits connus, dont plus de 60 cannabinoïdes. L’ingrédient psychoactif majeur de la marijuana et du haschich est le delta-9-tétrahydrocannabinol (THC).Outre l’euphorie, le cannabis entraîne divers effets aigus et chroniques affectant principalement… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2006
2006
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 63 publications
0
3
0
Order By: Relevance
“…Now is being developed by CymaBay Therapeutics [56]. Seladelpar (21) was under Phase III clinical trials for the treatment of primary biliary cholangitis, a chronic liver disease with a higher prevalence in women than in men [57][58][59]. Primary biliary cholangitis is an autoimmune disease characterized by progressive destruction of the small bile ducts of the liver, the cholangiocytes, causing bile to build up in the liver, a condition designated by cholestasis [60].…”
Section: Paclitaxel Cabazitaxel Docetaxelmentioning
confidence: 99%
See 2 more Smart Citations
“…Now is being developed by CymaBay Therapeutics [56]. Seladelpar (21) was under Phase III clinical trials for the treatment of primary biliary cholangitis, a chronic liver disease with a higher prevalence in women than in men [57][58][59]. Primary biliary cholangitis is an autoimmune disease characterized by progressive destruction of the small bile ducts of the liver, the cholangiocytes, causing bile to build up in the liver, a condition designated by cholestasis [60].…”
Section: Paclitaxel Cabazitaxel Docetaxelmentioning
confidence: 99%
“…Seladelpar synthesis: In 2005, Kuo and co-workers [63] from Janssen Pharmaceutica N.V. fi led a patent (WO2005042478 A2) claiming the preparation of 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, which includes Seladelpar (21) (CAS number: 851528-79-5). Seladelpar (21) was prepared by a convergent synthesis starting from intermediates 24 and 27. Intermediate 24 was prepared by sulfonating the benzenic ring of (2-methylphenoxy) acetate 22 with chlorosulfonic acid to aff ord 23.…”
Section: Paclitaxel Cabazitaxel Docetaxelmentioning
confidence: 99%
See 1 more Smart Citation